JANX

Janux Therapeutics Stock Analysis

AI Rating

Low
  • Quality3/10
  • Growth↓ 0/10
  • Value↓ 0/10
Janux Therapeutics sales and earnings growth
JANX Growth
Low
  • Revenue Y/Y↓ -5.55%
  • EPS Y/Y↓ -42.97%
  • FCF Y/Y↓ -88.53%
Janux Therapeutics gross and profit margin trends
JANX Profitability
Low
  • Gross margin ↑ 100.00%
  • EPS margin↓ -1136.30%
  • ROIC 5Y↓ -14.07%
Janux Therapeutics net debt vs free cash flow
JANX Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↑ 999.0

Janux Therapeutics stock volatility is in-line with the overall market. We give it a Great risk rating.

More Biotechnology stocks ↗